Market Cap 79.47M
Revenue (ttm) 124.96M
Net Income (ttm) -21.58M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -17.27%
Debt to Equity Ratio 0.37
Volume 53,500
Avg Vol 51,644
Day's Range N/A - N/A
Shares Out 6.42M
Stochastic %K 62%
Beta 0.77
Analysts Strong Sell
Price Target $38.94

Company Profile

Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut sy...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 224 419 7106
Fax: 510 744 8001
Address:
100 South Saunders Road, Suite 300, Lake Forest, United States
Avedisian
Avedisian Feb. 13 at 4:30 PM
$ASRT Technically ASRT looks primed to break out above 15, there has been healthy volume since RS, somebody is buying, provided there is good news. Lets hope in March ER they give guidance for 2026. For Q4 total revenue till now is 105.17 they said 110-112, analyst estimates say 4.75-5m in Q4. Lets see.
2 · Reply
Chuckuk
Chuckuk Feb. 13 at 2:55 PM
$ASRT On Fintel this is now 221 on the list of short Squeeze likely candidates Short Squeeze Score from Fintel The Short Squeeze Score is the result of a sophisticated, multi-factor quantitative model that identifies companies that have the highest risk of experiencing a short squeeze. The scoring model uses a combination of short interest, float, short borrow fee rates, and other metrics. The number ranges from 0 to 100, with higher numbers indicating a higher risk of a short squeeze relative to its peers, and 50 being the average. 75.17 221 out of 4083
2 · Reply
D_S
D_S Feb. 12 at 6:28 PM
$ASRT 1 month till Q4 report and some kind of update from company. As far as "Assertio Specialty Pharmaceuticals"----they switched the FDA labeling for Rolvedon from Spectrum Pharmaceuticals over to the new subsidiary, but nothing else was. I'm sure there is some purpose to it all (as the whole process started over 9 months ago with trademark for subsidiary was created) but company doesn't seem interested in explaining it all (yet? ever?).
1 · Reply
BlackImpulse
BlackImpulse Feb. 10 at 1:46 PM
$ASRT is a biotech (Assertio Holdings) with a neurology focus; has faced commercial and strategic challenges.
1 · Reply
Luckybreak
Luckybreak Feb. 10 at 1:22 PM
$ASRT This is possibly one of the cheapest stock in Wall Street Market cap 77 million /Rolvedon expected to generate more than $50 million / $50M in net cash A private entity can take it out for $400 million 5 times the present stock price. Wall Street /what is racket
1 · Reply
Fearnot
Fearnot Feb. 9 at 8:09 PM
$ASRT isnt it funny how eva since the RS its only gone up...🙄🤣😂 seems like somebody was saying that a long time ago!
1 · Reply
Invest2live
Invest2live Feb. 6 at 9:54 PM
$ASRT 23% already; 15+ coming Do your DD and get in.
0 · Reply
TheFingerBlast
TheFingerBlast Feb. 6 at 9:38 PM
$ASRT Strongest close in a while. Next week we getting fingered again?
1 · Reply
11thestate
11thestate Feb. 5 at 3:54 PM
$ASRT has agreed to settle with investors over claims that it misled them about the effectiveness and FDA approval prospects of its two lead drug candidates. Who’s eligible? Anyone who purchased $ASRT shares between December 19, 2018 and August 30, 2021. Do I need to sell my shares to qualify? No — you are eligible whether you sold your shares or still hold them. How much is the payout? The payout per share is $0.06 — but normally only ~25% of eligible investors file, the effective payout could increase to $0.24. Can I still file? Yes — late claims are currently being considered for compensation, subject to approval. When do payouts happen? Typically within 8–12 months after court approval of the settlement. To file your claim: https://11th.com/cases/spectrum-investor-settlement
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 4 at 7:31 PM
$ASRT RSI: 68.97, MACD: 0.4143 Vol: 1.07, MA20: 11.12, MA50: 10.89 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Latest News on ASRT
Assertio Holdings, Inc. Announces 1-for-15 Reverse Stock Split

Dec 22, 2025, 4:30 PM EST - 7 weeks ago

Assertio Holdings, Inc. Announces 1-for-15 Reverse Stock Split


Assertio Holdings, Inc. (ASRT) Q3 2025 Earnings Call Transcript

Nov 10, 2025, 6:21 PM EST - 3 months ago

Assertio Holdings, Inc. (ASRT) Q3 2025 Earnings Call Transcript


Assertio Reports Third Quarter 2025 Financial Results

Nov 10, 2025, 4:13 PM EST - 3 months ago

Assertio Reports Third Quarter 2025 Financial Results


Assertio Announces Leadership Transition

Oct 28, 2025, 9:15 AM EDT - 3 months ago

Assertio Announces Leadership Transition


Assertio Holdings, Inc. (ASRT) Q2 2025 Earnings Call Transcript

Aug 11, 2025, 7:41 PM EDT - 6 months ago

Assertio Holdings, Inc. (ASRT) Q2 2025 Earnings Call Transcript


Assertio Reports Second Quarter 2025 Financial Results

Aug 11, 2025, 4:05 PM EDT - 6 months ago

Assertio Reports Second Quarter 2025 Financial Results


Assertio Holdings, Inc. (ASRT) Q1 2025 Earnings Call Transcript

May 12, 2025, 8:17 PM EDT - 9 months ago

Assertio Holdings, Inc. (ASRT) Q1 2025 Earnings Call Transcript


Assertio Reports First Quarter 2025 Financial Results

May 12, 2025, 4:01 PM EDT - 9 months ago

Assertio Reports First Quarter 2025 Financial Results


Assertio Reports Third Quarter 2024 Financial Results

Nov 11, 2024, 4:02 PM EST - 1 year ago

Assertio Reports Third Quarter 2024 Financial Results


Assertio Provides Response to Letter from Short-seller

Nov 11, 2024, 7:30 AM EST - 1 year ago

Assertio Provides Response to Letter from Short-seller


Assertio Reports Second Quarter 2024 Financial Results

Aug 7, 2024, 4:01 PM EDT - 1 year ago

Assertio Reports Second Quarter 2024 Financial Results


Assertio: An Extremely Asymmetric Bet Skewed To The Upside

Jun 27, 2024, 9:51 AM EDT - 1 year ago

Assertio: An Extremely Asymmetric Bet Skewed To The Upside


Avedisian
Avedisian Feb. 13 at 4:30 PM
$ASRT Technically ASRT looks primed to break out above 15, there has been healthy volume since RS, somebody is buying, provided there is good news. Lets hope in March ER they give guidance for 2026. For Q4 total revenue till now is 105.17 they said 110-112, analyst estimates say 4.75-5m in Q4. Lets see.
2 · Reply
Chuckuk
Chuckuk Feb. 13 at 2:55 PM
$ASRT On Fintel this is now 221 on the list of short Squeeze likely candidates Short Squeeze Score from Fintel The Short Squeeze Score is the result of a sophisticated, multi-factor quantitative model that identifies companies that have the highest risk of experiencing a short squeeze. The scoring model uses a combination of short interest, float, short borrow fee rates, and other metrics. The number ranges from 0 to 100, with higher numbers indicating a higher risk of a short squeeze relative to its peers, and 50 being the average. 75.17 221 out of 4083
2 · Reply
D_S
D_S Feb. 12 at 6:28 PM
$ASRT 1 month till Q4 report and some kind of update from company. As far as "Assertio Specialty Pharmaceuticals"----they switched the FDA labeling for Rolvedon from Spectrum Pharmaceuticals over to the new subsidiary, but nothing else was. I'm sure there is some purpose to it all (as the whole process started over 9 months ago with trademark for subsidiary was created) but company doesn't seem interested in explaining it all (yet? ever?).
1 · Reply
BlackImpulse
BlackImpulse Feb. 10 at 1:46 PM
$ASRT is a biotech (Assertio Holdings) with a neurology focus; has faced commercial and strategic challenges.
1 · Reply
Luckybreak
Luckybreak Feb. 10 at 1:22 PM
$ASRT This is possibly one of the cheapest stock in Wall Street Market cap 77 million /Rolvedon expected to generate more than $50 million / $50M in net cash A private entity can take it out for $400 million 5 times the present stock price. Wall Street /what is racket
1 · Reply
Fearnot
Fearnot Feb. 9 at 8:09 PM
$ASRT isnt it funny how eva since the RS its only gone up...🙄🤣😂 seems like somebody was saying that a long time ago!
1 · Reply
Invest2live
Invest2live Feb. 6 at 9:54 PM
$ASRT 23% already; 15+ coming Do your DD and get in.
0 · Reply
TheFingerBlast
TheFingerBlast Feb. 6 at 9:38 PM
$ASRT Strongest close in a while. Next week we getting fingered again?
1 · Reply
11thestate
11thestate Feb. 5 at 3:54 PM
$ASRT has agreed to settle with investors over claims that it misled them about the effectiveness and FDA approval prospects of its two lead drug candidates. Who’s eligible? Anyone who purchased $ASRT shares between December 19, 2018 and August 30, 2021. Do I need to sell my shares to qualify? No — you are eligible whether you sold your shares or still hold them. How much is the payout? The payout per share is $0.06 — but normally only ~25% of eligible investors file, the effective payout could increase to $0.24. Can I still file? Yes — late claims are currently being considered for compensation, subject to approval. When do payouts happen? Typically within 8–12 months after court approval of the settlement. To file your claim: https://11th.com/cases/spectrum-investor-settlement
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 4 at 7:31 PM
$ASRT RSI: 68.97, MACD: 0.4143 Vol: 1.07, MA20: 11.12, MA50: 10.89 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Invest2live
Invest2live Feb. 3 at 8:29 PM
$CSCO 75% already; congrats 🎈🌿🎈 Checkout $ASRT and AKBA with similar opportunities. $MSFT is a buy; do your DD and get in.
0 · Reply
Nvrstoplrning
Nvrstoplrning Feb. 3 at 1:24 PM
$ASRT https://finance.yahoo.com/news/wall-street-analysts-see-230-145503244.html
0 · Reply
Chrissytina
Chrissytina Feb. 2 at 4:52 PM
$ASRT 🤔 interesting 🤔
1 · Reply
Avedisian
Avedisian Jan. 27 at 6:15 PM
$ASRT For $ASRT to goto next level and attract traders needs to break 15 resistance, right now 200dma is flat, once it breaks 200dma will be in upswing and 50dma would have crossed over to make golden cross. $15 is magic no for CANSLIM(ONeil traders) that should bring another crowd. I think the mgmt has to release good news carefully pipelined surely not bad news hopefully we are done with it.
1 · Reply
caddaly
caddaly Jan. 26 at 7:48 PM
$ASRT wheres mr. sword swinger. Last I heard he hated the stock at 9
1 · Reply
Avedisian
Avedisian Jan. 25 at 5:45 PM
$ASRT Interesting Hanmi mentions Rolvedon as one of the drugs for increased profits in 2025 hopefully this will continue into 2026 even more. "Separately, Yeo forecast Hanmi Pharmaceutical’s 2025 consolidated revenue at 425.7billion won, up 21.1% year on year, with operating profit expected to surge 128.6% to 69.6 billion won. He attributed the strong outlook to increased sales of respiratory prescription drugs such as Hanmi Flu amid a severe influenza season, HIGHER ROYALTY INCOME FROM U.S. SALES OF NEUTROPENIA DRUG ROLVEDON, and revenue from supplying clinical trial materials to partners." https://www.businesskorea.co.kr/news/articleView.html?idxno=261572
0 · Reply
D_S
D_S Jan. 22 at 6:49 PM
$ASRT They will be at April 28-29th Community Oncology Conference. They are a sponsor and most likely will be an exhibitor too. https://coaconference.com/exhibitors-sponsors/#sponsors
0 · Reply
caddaly
caddaly Jan. 20 at 4:35 PM
$ASRT it would be nice if someone was making markets in the options!
0 · Reply
caddaly
caddaly Jan. 20 at 4:33 PM
$ASRT lets get some momentum.
0 · Reply
Avedisian
Avedisian Jan. 19 at 5:12 PM
$ASRT There is MSRP and then there is the real price after rebates, discounts. The real price is what CMS releases from Medicaid which approximates what clinics & hospitals pay. In there Neulasta and biosimilars are about 1-1.5k whereas Rolvedon is about 2.5k or so BUT here is the catch, Medicaid reimburses for cost of drug with 6% 🤔 Now you can guess which side some oncology clinics will go, this is how they have oncology clinic mkt share. Watch the Brendan Grady interview posted by @berlinboy101 Brendan explains how this mkt works. He says there is enough opportunity to get to 100m. He also says hospital mkt is price sensitive to compete they lowball you to the point of disappearing. Insurance won't necessarily go for low cost, it will go for overall low cost. People who have been holding this for longer know that Indocin used to be one of most expensive drugs $800 but it prevented a hospitlization which would cost about $2000, being offlabel tsustained ASRT for years.
1 · Reply
caddaly
caddaly Jan. 18 at 8:05 PM
$ASRT For a large hospital in NJ, their contracted price for Neulasta, which is on their formulary, is 4260 per dose. Rolvedon, which is not on their formulary, and they currently don’t have a contract price, is 4420 per dose. They currently order a high volume of Neulasta. They normally have the patient back to the hospital the next day for the dose of Neulasta, but the docs don’t like them back in the hospital because they are immuno compromised. Sometimes space for the return visit is an issue. If possible, they send a home health aide to administer the dose, give them the auto injector, or teach them how to self-administer. They do run into problems with older patients in these scenarios. It’s a long process to get on the hospital formulary, Doctor has to recommend and then Board approval. That was from Director of Pharmacy. She didnt know anything about Rolvedon. Hasnt heard any docs speak about it.
3 · Reply
Blue_mist
Blue_mist Jan. 17 at 1:43 PM
$ASRT when we see $250 ? Am stuck there
1 · Reply